![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Population Health Investment Company Inc | NASDAQ:PHIC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.07 | 10.07 | 10.09 | 0 | 01:00:00 |
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Cayman Islands
|
001-39706
|
98-1556837
|
||
(State or other jurisdiction of
incorporation or organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification Number)
|
One World Financial Center
New York, NY
|
10281
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
Units, each consisting of one Class A ordinary share and
one-third
of a Warrant to acquire one Class A ordinary share
|
PHICU
|
The Nasdaq Stock Market LLC
|
||
Class A ordinary shares, par value $0.0001 per share
|
PHIC
|
The Nasdaq Stock Market LLC
|
||
Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
|
PHICW
|
The Nasdaq Stock Market LLC
|
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer
|
☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
September 30, 2021
|
December 31, 2020
|
|||||||
(Unaudited)
|
||||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash
|
$ | 372,687 | $ | 681,243 | ||||
Prepaid expenses
|
519,095 | 860,685 | ||||||
|
|
|
|
|||||
Total current assets
|
891,782 | 1,541,928 | ||||||
Investments held in Trust Account
|
172,521,754 | 172,500,227 | ||||||
|
|
|
|
|||||
Total Assets
|
$
|
173,413,536
|
|
$
|
174,042,155
|
|
||
|
|
|
|
|||||
Liabilities, Class
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$ | 10,099 | $ | 78,315 | ||||
Accrued expenses
|
481,000 | 70,000 | ||||||
Note payable
-
related party
|
300,000 | 300,000 | ||||||
|
|
|
|
|||||
Total current liabilities
|
791,099 | 448,315 | ||||||
Deferred underwriting commissions
|
6,037,500 | 6,037,500 | ||||||
Derivative warrant liabilities
|
7,037,500 | 12,234,170 | ||||||
Due to related party
|
|
|
246,938
|
|
|
|
—
|
|
|
|
|
|
|||||
Total liabilities
|
14,113,037 | 18,719,985 | ||||||
Commitments and Contingencies
|
||||||||
Class A ordinary shares subject to possible redemption, $0.0001 par value; 17,250,000 shares at $10.00 per share redemption value at September 30, 2021 and December 31, 2020
|
172,500,000 | 172,500,000 | ||||||
Shareholders’ Deficit
|
||||||||
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2021 and December 31, 2020
|
— | — | ||||||
Class A ordinary shares, $0.0001 par value; 300,000,000 shares authorized at September 30, 2021 and December 31, 2020
|
— | — | ||||||
Class B ordinary shares, $0.0001 par value; 30,000,000 shares authorized; 4,312,500 shares issued and outstanding at September 30, 2021 and December 31, 2020
|
431 | 431 | ||||||
Additional
paid-in
capital
|
— | — | ||||||
Accumulated deficit
|
(13,199,932 | ) | (17,178,261 | ) | ||||
|
|
|
|
|||||
Total shareholders’ deficit
|
(13,199,501 | ) | (17,177,830 | ) | ||||
|
|
|
|
|||||
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
|
$
|
173,413,536
|
|
$
|
174,042,155
|
|
||
|
|
|
|
|
|
For The Three Months
Ended September 30, 2021 |
|
|
For The Nine Months Ended
September 30, 2021 |
|
|
For The Period From
September
11
, 2020
(Inception) Through September 30, 2020 |
|
|||
General and administrative expenses
|
$ | 525,460 | $ | 1,239,868 | $ | 33,376 | ||||||
|
|
|
|
|
|
|||||||
Loss from operations
|
(525,460 | ) | (1,239,868 | ) | (33,376 | ) | ||||||
Other income
|
||||||||||||
Change in fair value of derivative warrant liabilities
|
3,753,330 | 5,196,670 | — | |||||||||
Net gain from investments held in Trust Account
|
15,148 | 21,527 | — | |||||||||
|
|
|
|
|
|
|||||||
Net income (loss)
|
$ | 3,243,018 | $ | 3,978,329 | $ | (33,376 | ) | |||||
|
|
|
|
|
|
|||||||
Weighted average shares outstanding of Class
A ordinary shares, basic and diluted |
17,250,000 | 17,250,000 | — | |||||||||
|
|
|
|
|
|
|||||||
Basic and diluted net income per share, Class A ordinary shares
|
$ | 0.15 | $ | 0.18 | $ | — | ||||||
|
|
|
|
|
|
|||||||
Weighted average shares outstanding of Class
B ordinary shares, basic and diluted |
4,312,500 | 4,312,500 | 3,750,000 | |||||||||
|
|
|
|
|
|
|||||||
Basic and diluted net income (loss) per share, Class B ordinary shares
|
$ | 0.15 | $ | 0.18 | $ | (0.01 | ) | |||||
|
|
|
|
|
|
|
|
Ordinary Shares
|
|
|
Additional
Paid-in Capital |
|
|
Accumulated
Deficit |
|
|
Total
Shareholders’ Deficit |
|
||||||||||||||||
|
|
Class A
|
|
|
Class B
|
|
||||||||||||||||||||||
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
||||||||||||||||
Balance - December 31, 2020
|
|
—
|
|
$
|
—
|
|
|
4,312,500
|
|
$
|
431
|
|
$
|
—
|
|
$
|
(17,178,261
|
)
|
$
|
(17,177,830
|
)
|
|||||||
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
1,785,072 | 1,785,072 | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - March 31, 2021 (Unaudited)
|
|
—
|
|
|
—
|
|
|
4,312,500
|
|
|
431
|
|
|
—
|
|
|
(15,393,189
|
)
|
|
(15,392,758
|
)
|
|||||||
Net loss
|
— | — | — | — | — | (1,049,761 | ) | (1,049,761 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - June 30, 2021 (Unaudited)
|
|
—
|
|
|
—
|
|
|
4,312,500
|
|
|
431
|
|
|
—
|
|
|
(16,442,950
|
)
|
|
(16,442,519
|
)
|
|||||||
Net income
|
— | — | — | — | — | 3,243,018 | 3,243,018 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - September 30, 2021 (Unaudited)
|
|
—
|
|
$
|
—
|
|
|
4,312,500
|
|
$
|
431
|
|
$
|
—
|
|
$
|
(13,199,932
|
)
|
$
|
(13,199,501
|
)
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary Shares
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
Total
Shareholders’ Deficit |
|||||||||||||||||||||||||
Class A
|
Class B
|
|||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||||||||||||||
Balance - September 11, 2020 (inception)
|
|
—
|
|
$
|
—
|
|
|
—
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
|||||||
Issuance of Class B ordinary shares to Sponsor
|
|
—
|
|
|
—
|
|
4,312,500 | 431 | 24,569 |
|
—
|
|
25,000 | |||||||||||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
(33,376 | ) | (33,376 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Balance - September 30, 2020 (Unaudited)
|
|
—
|
|
$
|
—
|
|
|
4,312,500
|
|
$
|
431
|
|
$
|
24,569
|
|
$
|
(33,376
|
)
|
$
|
(8,376
|
)
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For The Nine Months Ended
September 30, 2021 |
For The Period From
September 11, 2020 (inception) Through September 30, 2020 |
|||||||
Cash Flows from Operating Activities:
|
||||||||
Net
income (loss)
|
$ | 3,978,329 | $ | (33,376 | ) | |||
Adjustments to reconcile net
income (loss)
to net cash used in operating activities:
|
||||||||
Net gain from investments held in Trust Account
|
(21,527 | ) | — | |||||
Change in fair value of derivative warrant liabilities
|
(5,196,670 | ) | — | |||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses
|
341,590 | — | ||||||
Accounts payable
|
(68,216 | ) | — | |||||
Accrued expenses
|
411,000 | 33,376 | ||||||
Due to related party
|
|
|
246,938
|
|
|
|
—
|
|
|
|
|||||||
Net cash used in operating activities
|
(308,556 | ) | — | |||||
|
|
|
|
|||||
Net change in cash
|
(308,556 | ) | — | |||||
Cash - beginning of the period
|
681,243 | — | ||||||
|
|
|
|
|||||
Cash - end of the period
|
$
|
372,687
|
|
$
|
—
|
|
||
|
|
|
|
|||||
Supplemental disclosure of
non-cash
investing and financing activities:
|
||||||||
Offering costs included in accrued expenses
|
$ | — | $ | 244,605 | ||||
Offering costs included in accounts payable
|
$ | — | $ | 10,000 | ||||
Offering costs paid in exchange for issuance of Class B ordinary shares to Sponsor
|
$ | — | $ | 25,000 |
|
|
As of December 31, 2020
|
|
|||||||||
|
|
As Previously Reported (1)
|
|
|
Adjustment
|
|
|
As Revised
|
|
|||
Equity Components
|
|
|
|
|||||||||
Class A ordinary share subject to possible
redemption |
|
|
|
|||||||||
Class A ordinary share, $0.0001 par value; shares subject to possible redemption
|
$
|
150,322,160 |
$
|
22,177,840 |
$
|
172,500,000 | ||||||
Shareholders’ equity (deficit)
|
||||||||||||
Preferred stock - $0.0001 par value
|
— | — | — | |||||||||
Class A ordinary share - $0.0001 par value
|
222 | (222 | ) | — | ||||||||
Class B ordinary share - $0.0001 par value
|
431 | — | 431 | |||||||||
Additional
paid-in-capital
|
|
|
7,101,932 |
|
|
|
(7,101,932 |
)
|
|
|
—
|
|
Accumulated deficit
|
(2,102,575 | ) | (15,075,686 | ) | (17,178,261 | ) | ||||||
|
|
|
|
|
|
|||||||
Total shareholders’ equity (deficit)
|
5,000,010 | (22,177,840 | ) | (17,177,830 | ) | |||||||
|
|
|
|
|
|
|||||||
Total liabilities, Class A ordinary share subject to possible redemption and shareholders’ equity
(deficit) |
$ | 174,042,155 | $ | — | $ | 174,042,155 | ||||||
|
|
|
|
|
|
(1) |
As reported in the Company’s Annual Report on Form
10-K/A
for the year ended December 31, 2020, as filed with the SEC on May 24, 2021.
|
• |
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
|
• |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
|
• |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
|
|
|
For the Three Months Ended
September 30, 2021 |
|
|
For the Nine Months Ended
September 30, 2021 |
|
|
For the Period From
September
11
,
2020 (Inception) Through September 30, 2020 |
|
|||||||||||||||
|
|
Class A
|
|
|
Class B
|
|
|
Class A
|
|
|
Class B
|
|
|
Class A
|
|
|
Class B
|
|
||||||
Basic and diluted net income (loss) per ordinary share:
|
|
|
|
|
|
|
||||||||||||||||||
Numerator:
|
||||||||||||||||||||||||
Allocation of net income (loss)
|
2,594,414 | 648,604 | 3,182,663 | 795,666 | — | (33,376 | ) | |||||||||||||||||
Denominator:
|
||||||||||||||||||||||||
Basic and diluted weighted average ordinary shares outstanding
|
17,250,000 | 4,312,500 | 17,250,000 | 4,312,500 | — | 3,750,000 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Basic and diluted net income (loss) per ordinary share
|
$ | 0.15 | $ | 0.15 | $ | 0.18 | $ | 0.18 | $ | — | $ | (0.01 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
• |
in whole and not in part;
|
• |
at a price of $0.01 per warrant;
|
• |
upon a minimum of 30 days’ prior written notice of redemption; and
|
• |
if, and only if, the last reported sale price (the “closing price”) of the Class A ordinary shares equals or exceeds $18.00 per share (share
sub-divisions,
share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a
30
-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”).
|
• |
in whole and not in part;
|
• |
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the “fair market value” of the Class A ordinary shares (as defined below);
|
• |
if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per Public Share (as adjusted per share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before the Company sends the notice of redemption to the warrant holders; and
|
• |
if the Reference Value is less than $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), then the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder’s ability to cashless exercise its warrants) as the outstanding Public Warrants as described above.
|
Gross proceeds
|
$ | 172,500,000 | ||
Less:
|
||||
Fair value of Public Warrants at issuance
|
(6,531,260 | ) | ||
Offering costs allocated to Class A ordinary shares subject to possible redemption
|
(9,769,025 | ) | ||
Plus:
|
||||
Accretion on Class A ordinary shares subject to possible redemption amount
|
16,300,285 | |||
|
|
|||
Class A ordinary shares subject to possible redemption
|
$ | 172,500,000 | ||
|
|
Description
|
|
Quoted Prices in Active
Markets
(Level 1)
|
|
|
Significant Other
Observable Inputs
(Level 2)
|
|
|
Significant Other
Unobservable Inputs
(Level 3)
|
|
|||
Assets:
|
|
|
|
|||||||||
Investments held in Trust Account – U.S. Treasury Securities
|
$ | 172,521,754 | $ | — | $ | — | ||||||
Liabilities:
|
||||||||||||
Derivative warrant liabilities - Public
|
$ | 4,312,500 | $ | — | $ | — | ||||||
Derivative warrant liabilities - Private
|
$ | — | $ |
2,725,000
|
$ | — |
Description
|
Quoted Prices
in Active
Markets
(Level 1)
|
Significant
Other
Observable
Inputs
(Level 2)
|
Significant
Other
Unobservable
Inputs
(Level 3)
|
|||||||||
Assets:
|
||||||||||||
Money market funds
|
$ | 172,500,227 | $ | — | $ | — | ||||||
Liabilities:
|
||||||||||||
Derivative warrant liabilities
|
$ | — | $ | — | $ | 12,234,170 |
As of
December 31, 2020 |
||||
Volatility
|
20.0 | % | ||
Stock price
|
$ | 10.02 | ||
Expected life of the options to convert
|
5.84 | |||
Risk-free rate
|
0.48 | % | ||
Dividend yield
|
0.0 | % |
Level 3 - Derivative warrant liabilities at December 31, 2020
|
$ | 12,234,170 | ||
Change in fair value of derivative warrant liabilities
|
(795,070 | ) | ||
Transfer of Public Warrants out of level 3
|
(7,442,430 | ) | ||
|
|
|||
Level 3 - Derivative warrant liabilities at March 31, 2021
|
3,996,670 | |||
Change in fair value of derivative warrant liabilities
|
181,660 | |||
|
|
|||
Level 3 - Derivative warrant liabilities at June 30, 2021
|
4,178,330 | |||
Transfer of Private Warrants out of level 3
|
(4,178,330 | ) | ||
|
|
|||
Level 3 - Derivative warrant liabilities at September 30, 2021
|
$ | — | ||
|
|
• |
our ability to select an appropriate target business or businesses;
|
• |
our ability to complete our initial business combination;
|
• |
our expectations around the performance of the prospective target business or businesses;
|
• |
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
|
• |
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination;
|
• |
our potential ability to obtain additional financing to complete our initial business combination;
|
• |
our pool of prospective target businesses;
|
• |
our ability to consummate our initial business combination due to the uncertainty resulting from the ongoing
COVID-19
pandemic and other events (such as terrorist attacks, natural disasters or other significant outbreaks of infectious diseases);
|
• |
the ability of our officers and directors to generate a number of potential acquisition opportunities;
|
• |
our public securities’ potential liquidity and trading;
|
• |
the lack of a market for our securities;
|
• |
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;
|
• |
the proceeds from the sale of the Forward Purchase Units (as defined below) being available to us;
|
• |
the trust account not being subject to claims of third parties; or
|
• |
our financial performance in the future.
|
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* |
Filed herewith.
|
** |
Furnished.
|
POPULATION HEALTH INVESTMENT CO., INC.
|
||||||
Date:
November 12, 2021
|
By: |
/s/ Chris Visioli
|
||||
Name: | Chris Visioli | |||||
Title: | Chief Financial Officer | |||||
(Principal Financial and Accounting Officer) |
1 Year Population Health Invest... Chart |
1 Month Population Health Invest... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions